Asthma Spacers Market Analysis Report 2027

 

The global Asthma Spacers Market is forecasted to be worth USD 2.38 Billion by 2027, according to a current analysis by Emergen Research.  The asthma spacers market is majorly driven by rising respiratory disorder incidence. For instance, as per the American College of Allergy, Asthma & Immunology in Americans, 8.3% have asthma, 20.4 million are adults, and 6.1 million are children. Besides, the increasing amount of investment by government and healthcare agencies to reduce respiratory illnesses and also to raise public awareness of this product is expected to further propel the market growth over the forecast timeline. Moreover, rising small players' entrance in the market enables low-cost products, which is also expected to fuel the market growth shortly.

Key Highlights From The Report

In September 2018, Allergan plc acquired Bonti, Inc. The addition of Bonti is a strategic investment in its medical aesthetics company's growth and has the opportunity to boost its best-in-class medicinal aesthetics portfolio.

Over the forecast period, the Aerochamber segment is forecasted to hold the largest market with a CAGR of 3.6%. It is easier to use for persons who have a hard time handling the hand to mouth method. There are fewer side effects with the use of an aero-chamber since less medication is processed in the back of the mouth.

Compared to retail and hospital pharmacies, the growing amount of internet users and the accessibility of asthma spacers online at a lower cost, which is expected to stimulate the growth of the e-commerce sector rapidly.

Over the forecast timeline, the clinics & hospital segment is anticipated to dominate the market as asthma leads to 439,000 hospitalizations and 1.3 million annual emergency visits.

The region of North America is anticipated to hold the largest market over the forecast period. The factor that has resulted in market growth is the increasing asthma incidence and raising awareness of the use of asthma spacers in the region.

Key participants include Lupin Limited, Trudell Medical Group Ltd., GlaxoSmithKline plc, Cipla Limited, Merck & Co., Inc, Clement Clarke International Ltd, PARI GmbH, AstraZeneca plc/AB, Fisons plc, and Allergan plc among others.

Request for sample report@ https://www.emergenresearch.com/request-sample/307

Type Outlook (Revenue, USD Billion; 2017-2027)

Inspirease

Optichamber

Aerochamber

Volumatic

Distribution Channel Outlook (Revenue, USD Billion; 2017-2027)

E-commerce

Retail Pharmacy

Hospital Pharmacy

End-Use Outlook (Revenue, USD Billion; 2017-2027)

Homecare

Clinics & Hospitals

Others

Regional Outlook (Revenue, USD Billion; 2017-2027)

North America

Europe

Asia Pacific

Latin America

MEA